ASP Isotopes Inc. Common Stock (ASPI) | The Buildout — AI Infrastructure
The Verdict
ASP Isotopes develops and operates isotope enrichment facilities, mostly in South Africa, that produce enriched materials for pharmaceutical, semiconductor, scientific and nuclear-fuel customers. Its most direct link to the AI buildout is enriched silicon-28, an isotope-pure input that improves electron mobility and thermal conductivity in advanced transistors; management does not frame the company as an AI play, and the connection runs through the semiconductor supply chain rather than a data-centre order. The rest of the portfolio sits in different demand cycles: HALEU for advanced reactors through majority-owned Quantum Leap Energy, Yb-176 and PET radiopharmacy for medical use, and helium and LNG from the Virginia Gas Plant. After acquiring Renergen in January 2026, ASPI operates South Africa's first integrated producer of liquid helium and LNG.
| Market Cap | — |
| Revenue (TTM) | $31M |
| Revenue Growth | +571.7% |
| EBITDA Margin (TTM) | -294.2% |
| Net Debt | $15M |
| Earnings Beats | 0 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- TerraPower HALEU agreement: 10 years, up to 150 metric tons, running 2028-2037, with a term-loan component.
- C-14: the entire plant capacity is under a tolling agreement with one unnamed Canadian customer, at a minimum take-or-pay of about $2.5M a year backed by a bank letter of guarantee, priced at $24k/gram.
- Yb-176: pricing discussed around $20k/gram against about 2 kg of indicated demand, roughly $40M of potential, from a plant that cost about $3M.
- Low capital cost per plant: the Yb-176 plant cost about $3M and was built in roughly two months, supported by an in-house engineering team that numbered about 130 at December 31, 2024 and about 150 by the Q4 2024 call.
- Balance sheet: $219.6M of cash plus $35.3M of short-term investments at June 30, 2026; interest income of $3.047M in Q1 2026 was larger than that quarter's gross profit.
What We’re Watching
- Q3 2026 is the concentrated test: C-14, Si-28 and Yb-176 all target first commercial shipments then, and the Q2 2026 10-Q (around August 2026) is the first place revenue would show.
- The cost base is far larger than the revenue base: $26.554M of operating expense in Q1 2026 against $4.18M of revenue, with the operating loss widening to $(24.888)M from $(7.952)M a year earlier.
- Debt jumped after the Renergen acquisition: total debt stood at $269.6M at June 30, 2026, up from $2.055M at December 31, 2025; the SBSA loan matured March 31, 2026 at a JIBAR-linked 21.725% and was being amended.
- Permits sit outside management's control: NNR uranium approval, laser export permits for the next-generation plants, and SAFRA approval for the PET Labs cyclotron.
The thesis rests on three first commercial isotope shipments plus a long-dated HALEU contract. Contracts and capital moves have been delivered — the TerraPower agreement, the Renergen acquisition, the proposed Noble Africa/ENDRA transaction — while every dated shipment promise in the record has moved later, and the company has not come in ahead of analyst estimates in any of the 7 tracked quarters. That mix keeps the case intact but untested on revenue. The open question is whether the Q3 2026 shipments actually appear in the next filing, or whether the pattern of extended timelines holds.
Earnings
In its June 2026 quarter, ASP Isotopes reported $5.1M of revenue at a 28.9% gross margin, with EBITDA of -$33.0M. Revenue rose from $1.2M in the year-ago quarter, while the EBITDA loss widened from -$11.4M. The three first isotope shipments were still targeted for Q3 2026 and had not been recognised.
| Metric | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $5M | $4M | $1M | +325.0% |
| Gross margin | 28.9% | 39.9% | 47.7% | -1880bps |
| EBITDA | −$33M | −$22M | −$11M | +189.5% |
| EPS | $-0.27 | $-0.06 | $-1.03 | −73.4% |
We haven't given guidance for the year. We don't intend to give guidance on this call.— Paul Mann, CEO, 28-Dec-2024
Management tone: No earnings call on record for the latest period; the most recent call in the material is the FY2024 Q4 call of 28-December-2024. On that call, management's tone was confident and engineering-led: Paul Mann framed the commissioning of three plants as validation that 'none of them go easily but they all went.' He reframed on formal guidance, deflected on the Oklo relationship citing NDAs, was direct on the QLE spin-out timeline and on the likelihood that Intel and TSMC will not publicly validate Si-28 results, and declined to comment on Cyclotron Centre Norway collaborations, also citing NDAs. On the short-seller report, management was direct but not panicked, letting operational delivery speak.
Management Guidance
ASP Isotopes has never issued formal revenue, margin or EPS guidance. On the Q4 2024 call, management said it would not guide and pointed instead to contract sums, and offered one aspiration — 'cash flow breakeven or better' in the second half of 2025 — that has never been confirmed or updated. What the company issues instead are timelines: first commercial Si-28 shipments targeted Q3 2026 (moved from Q2 2026), C-14 in Q3 2026 (moved from mid-2026 and conditional on customer feedstock timing and quality), and Yb-176 in Q3 2026 (moved from end-Q2 2025). Helium liquefaction is targeted to start in H2 2026, and Virginia Gas Project Phase 2 is estimated at approximately $1.16 billion, which the filer says could change.
Trajectory
Quarterly revenue ran near $1M through FY2024 and the first half of FY2025, then jumped to $16.7M in the December 2025 quarter and settled at $4.2M in March 2026 and $5.1M in June 2026, as acquisitions and the helium segment came on. Gross margin has been uneven — 50.7% in the December 2024 quarter, 8.7% in September 2025, 39.9% in March 2026 and 28.9% in June 2026. EBITDA losses and free cash outflow have widened over recent quarters, reaching -$33.0M and -$27.4M in the latest. Trailing-twelve-month revenue was $30.9M against EBITDA of -$90.9M and free cash flow of -$83.5M. The isotope shipments meant to change the revenue base had not begun.
The Model
The model projects FY+1 revenue of $27.35M and EBITDA of -$108M, a -394.0% margin. For FY+2 it projects revenue of $61.0M and EBITDA of -$84M, a -137.5% margin. The near-term anchor is the timing of first commercial isotope shipments and the helium segment's contribution; the FY+2 step assumes revenue roughly doubles as C-14, Si-28 and Yb-176 scale and the TerraPower HALEU contract moves toward its 2028 start.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $24M | $27M | $61M |
| YoY Growth | — | +14.4% | +123.0% |
| EBITDA | −$55M | −$108M | −$84M |
| EBITDA Margin | -231.4% | -394.0% | -137.5% |
Projections are the median of 4 independent model runs.
ASP Isotopes has never issued formal revenue, margin or EPS guidance. On the Q4 2024 call, management said it would not guide and pointed instead to contract sums, and offered one aspiration — 'cash flow breakeven or better' in the second half of 2025 — that has never been confirmed or updated. What the company issues instead are timelines: first commercial Si-28 shipments targeted Q3 2026 (moved from Q2 2026), C-14 in Q3 2026 (moved from mid-2026 and conditional on customer feedstock timing and quality), and Yb-176 in Q3 2026 (moved from end-Q2 2025). Helium liquefaction is targeted to start in H2 2026, and Virginia Gas Project Phase 2 is estimated at approximately $1.16 billion, which the filer says could change.
What Could Go Right — and Wrong
- The three first commercial isotope shipments land in Q3 2026 and are disclosed in the next filing, converting contract paper into recognised revenue.
- Laser export permits are granted, unlocking construction of the Ni-64, Gd-160 and Li-6 plants and turning the ~$3M-per-plant claim into a visible pipeline.
- A QLE listing filing surfaces the Nuclear Fuels business; the July 2026 note exchange already cut QLE's outstanding notes by roughly 50%.
- The proposed Noble Africa/ENDRA merger and $50M private placement close, creating a listed helium platform.
- Helium liquefaction starts in H2 2026, moving the Helium & LNG segment from a gross loss toward gross profit.
- Another round of shipment slippage; each of the three dates has already moved at least once.
- A C-14 feedstock failure or a pause by the single tolling customer idles a plant whose entire capacity is committed to that one counterparty.
- Si-28 pricing is cut toward the $20/gram aspiration before fab qualification is achieved, keeping the revenue contribution a stub for years.
- Laser export permits or NNR uranium approval are denied or delayed, freezing the next-generation plants and the 2028 HALEU start.
- Virginia Gas Project Phase 2 is estimated at roughly $1.16 billion against conditionally approved debt of up to $500M (DFC) and $250M (Standard Bank), leaving a funding gap.
Looking Ahead
Over the next 12 months the evidence centres on the Q3 2026 shipment window. C-14, Si-28 and Yb-176 all target first commercial shipments then, and the Q2 2026 10-Q (around August 2026) is the first place that revenue would show. Helium liquefaction is targeted to start in H2 2026, which would move the Helium & LNG segment from a gross loss toward gross profit. Pending items include the Noble Africa/ENDRA merger with its $50M placement, any QLE listing filing, and the close of the DFC and Standard Bank Phase 2 facilities — up to $500M and $250M conditionally approved against a roughly $1.16 billion estimate.
- ~Aug 2026Q2 2026 results — First hard look at whether Q3 shipments landed, plus cash and debt.
- Q3 2026First Si-28 shipments — Tests the restarted Pretoria plant on commercial product.
- Q3 2026First C-14 shipments — Conditional on the timing and quality of customer feedstock.
- Q3 2026First Yb-176 shipments — Turns about 2 kg of indicated demand into revenue.
- H2 2026Helium liquefaction start — Trigger for Helium & LNG to move off a gross loss.
- PendingQLE listing filing — Any S-1/10 filing would surface the Nuclear Fuels business.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $4M | $24M | $31M | +482.9% |
| Gross Margin | 38.0% | 24.6% | 18.3% | 1,338bps |
| EBITDA | −$26M | −$55M | −$91M | -113.5% |
| EBITDA Margin | -631.7% | -231.4% | -294.2% | +40,033bps |
| Net Income | −$32M | −$175M | −$132M | -442.1% |
| Free Cash Flow | −$28M | −$47M | −$84M | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)18.3%
- EBITDA Margin (TTM)-294.2%
- Net Margin (TTM)-427.5%
- ROIC-27.3%
- SBC / Revenue45.6%
The Company
ASP Isotopes is an advanced materials company that develops and operates isotope enrichment facilities, mostly in South Africa, and added natural gas and helium production in January 2026. It reports in three segments: Specialist Isotopes and Related Services (C-14, Si-28 and Yb-176 plus the PET Labs radiopharmacy), Nuclear Fuels (HALEU and Lithium-6 through majority-owned Quantum Leap Energy), and Helium and LNG. A legacy Construction Services segment does civil engineering in Hong Kong and is shrinking in relative importance.
The operation is built around low capital cost per plant: the Yb-176 facility cost about $3M and was built in roughly two months after procurement, and the company relies on an in-house engineering team that numbered about 130 at December 31, 2024 and about 150 by the Q4 2024 call. Its uranium work sits at Pelindaba under a partnership with Necsa, which supplies site, infrastructure and licensing support, and its helium and LNG asset is the Virginia Gas Plant in Free State Province. It has grown by acquisition as well as organically, adding Renergen, the U.S. radiopharmacies ECNP and Numed, and a QLE patent application.
Business Segments
Competitive Landscape
ASPI's stated differentiation is cost. Management's own framing is that 'our capital cost to build a plant is so low,' with a roughly $3M plant for Yb-176 built in about two months, against the capital intensity of centrifuge enrichment. The counter-argument carried in the material is explicit: government-funded competitors can offset that advantage with subsidies, and in nuclear fuel markets state backing has historically been decisive. For HALEU, the customer has alternative suppliers and ASPI's claim is cost, not exclusivity; for Si-28, replaceability is unknown and end-users are unlikely to publish validation data, so the market reads ASPI's position from its own contract flow.
- Centrus Energy (LEU)Direct competitor in HALEU by centrifuge, and already has a relationship with Oklo that could limit QLE's addressable market there.
- Cameco (CCJ)GLE laser enrichment with a DOE tails focus; a potential competitor to QLE's laser route and a uranium market participant.
- UrencoEstablished LEU+ enricher, named as a competitor in the product-map context.
Supply Chain
ASPI enriches isotopes for semiconductor, pharmaceutical, scientific and nuclear-fuel customers, and produces helium and LNG after the Renergen acquisition. It relies on commercially available lasers and on a limited set of third-party suppliers for plant components.